FRFarid Rashidi

Farid Rashidi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Farid Rashidi has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Rezayat Parvizi

    Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    7 shared publications
  • Ata Koohi

    Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    6 shared publications
  • Babak Mahmoudian

    Medical Radiation Sciences Research Team, Tabriz University of Medical Sciences, Tabriz, Iran

    4 shared publications
  • Khalil Ansarin

    Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    4 shared publications
  • Ata Koohi

    Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    3 shared publications
  • Eisa Bilehjani

    Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    3 shared publications

Latest Publications

  • Incidence of pulmonary hypertension in patients with Takayasu's arteritis: A transthoracic echocardiographic evaluation

    by Ata Koohi, Farid Rashidi, Davood Attaran, Zahra Mirfeizi, Mohammad Hasan Jokar, Alireza Khabbazi, Mehrzad Hajalilou, Ehsan Ramezanian Nik, Hoorac Poorzand, Soroush Attaran, et al.

  • Chronic thromboembolic pulmonary hypertension: a narrative review of epidemiology, diagnosis, and treatment

    by Farid Rashidi

    Background. Pulmonary hypertension is an abnormal hemodynamic condition classified into 5 major groups. Chronic thromboembolic pulmonary hypertension (CTEPH) is the main representative of group 4 and the only potentially curable form. This review aimed to summarize current evidence on the epidemiology, pathophysiology, diagnostic approaches, and treatment options for CTEPH. Methods. In this narrative review, we searched PubMed, Scopus, and Google Scholar databases up to June 2025 using the keywords "Chronic Thromboembolic Pulmonary Hypertension", "CTEPH", "diagnosis", and "treatment". Relevant review articles, original studies, clinical guidelines, and authoritative Persian-language sources published in English or Persian were screened, and pertinent data were extracted. Results. CTEPH can occur at any age and in both genders, and early diagnosis is challenging because of its non-specific symptoms. Organized residual thrombi and small-vessel involvement constitute the core pathophysiology. Risk factors include coagulation disorders, prior splenectomy, and the presence of lupus anticoagulant. Diagnosis begins with echocardiography and ventilation–perfusion scanning and is confirmed by right-heart catheterization and detailed imaging. Treatment consists of pulmonary endarterectomy as the first-line option, balloon pulmonary angioplasty for inoperable patients, and medical/supportive therapy such as lifelong anticoagulation. Conclusion. CTEPH is a treatable cause of pulmonary hypertension, and early detection combined with appropriate treatment strategies can significantly improve disease course and patient survival. Multidisciplinary management in specialized centers, advanced imaging, and regular follow-up are essential to optimize outcomes and minimize complications. Practical Implications. Timely recognition in patients with a history of pulmonary embolism or persistent dyspnea is critical. Prompt referral to experienced centers for surgery or endovascular intervention can significantly enhance survival and quality of life.

  • Open Access

    Evaluation of Mortality and Morbidity in COVID-19 Patients Treated with NIV (Non-invasive Ventilation): A 30-Day Follow-up Study

    by Sahra Kuhkani, Fatemeh Zarghami, Neda Gilani, Farid Rashidi, Hourieh Shojaan, Leila Namvar

    Background: The COVID-19 pandemic has led to a surge in acute respiratory failure cases, necessitating effective management strategies. Non-invasive ventilation (NIV) has emerged as a treatment option; however, its efficacy and associated mortality rates remain debated. Objectives: This study aims to evaluate the mortality and morbidity rates in COVID-19 patients treated with NIV. Methods: We conducted a retrospective analysis of 50 patients diagnosed with COVID-19 [confirmed by positive nasopharyngeal polymerase chain reaction (PCR)] who received NIV at Imam Reza Hospital and Sina Medical Training Centers in Tabriz, Iran. Data were collected between April 2021 and January 2022, including demographic characteristics, clinical symptoms, laboratory findings, and outcomes, such as complications and mortality rates. For data analysis, we used logistic regression, the Mann-Whitney U test for comparing quantitative variables, and Fisher's exact test for qualitative variables. Results: Among the 50 patients, 28 (56%) died during hospitalization. The median age of non-survivors was 66 years, significantly higher than that of survivors (56 years, P = 0.018). Older age and higher Quick sepsis-related organ failure assessment (QSOFA) scores were predictive of increased mortality (OR = 1.24; P = 0.001). Additionally, complications such as pneumothorax were observed in 14% of patients. Conclusions: Our findings highlight a concerning mortality rate following NIV failure in COVID-19 patients, emphasizing the need for careful patient selection and close monitoring. Clinicians should consider early intubation for patients showing signs of NIV failure, particularly those with risk factors such as older age and high QSOFA scores.

  • Open Access

    Assessment of bleeding events in patients receiving DOACs with or without statins to treat venous thromboembolism: insights from the RIETE registry

    by Rosaria Del Giorno, Lucia Mazzolai, Sanjiv Keller, Carmine Siniscalchi, Luciano Lopez-Jimenez, Aitor Ballaz, Ana Cristina Montenegro, Remedios Otero, Farid Rashidi, Manuel Monreal

    Objective To evaluate the impact of coadministering statins with direct oral anticoagulants (DOACs) on the risk of major bleeding events in patients with venous thromboembolism (VTE). Design Observational cohort analysis based on a multicentre international registry. Setting Data were extracted from the Registro Informatizado de Enfermedad TromboEmbolica Registry, which involves 205 centres across 27 countries. Participants A total of 73 659 patients diagnosed with VTE were classified based on their anticoagulant therapy (DOACs) versus low-molecular-weight heparin (LMWH) or vitamin K antagonists (VKAs) and concurrent use of statins. Methods Multivariable Cox proportional hazards models adjusted for confounding variables to assess the risk of major bleeding events stratified by the type of anticoagulant use and statin use. Results From October 2013 to February 2023, 73 659 patients were recruited: 2573 were statin users on DOACs, 14 090 were statin users on LMWH or VKA therapy, 10 088 were non-statin users on DOACs and 46 908 were non-statin users on LMWH or VKA therapy. Statin users were 10 years older and more likely to have hypertension, diabetes, renal failure or prior artery disease. During anticoagulation (median, 187 days), 1917 patients (2.6%) suffered major bleeding. Rates of major bleeding per 100 patient-years were 2.33 (95% CI 1.72 to 3.09), 3.75 (95% CI 3.43 to 4.10), 1.39 (95% CI 1.13 to 1.69) and 3.10 (95% CI 2.93 to 3.27), respectively. On multivariable analysis, patients treated with DOACs had a significantly lower risk of major bleeding compared with those on LMWH or VKA therapy (adjusted HR 0.59; 95% CI 0.48 to 0.74). The adjusted HR in statin users versus non-users was 1.03 (95% CI 0.92 to 1.14), while in statin users on DOACs versus the rest of patients, it was 1.18 (95% CI 0.79 to 1.76). Conclusions In patients with VTE receiving statins, long-term anticoagulation with DOACs was associated with a reduced risk of major bleeding, regardless of the statin use. These findings support the safety profile of DOACs over VKAs or LMWH in the management of VTE in patients requiring statins.


  • Unilateral Chronic Thromboembolic Pulmonary Disease: Do Patients Benefit From Thromboendarterectomy? Case Series From Three CTEPH Centres

    by Farid Rashidi, Bedrettin Yıldızeli, Rezayat Parvizi, Serpil Taş, Şehnaz Olgun Yıldızeli, Bülent Mutlu, Eisa Bilehjani, Babak Mahmoudian, Hooman Bakhshandeh, Seyed Ali Mousavi-Aghdas, et al.


  • Thrombotic Disease in Thrombosis in Hematopoietic Stem Cell Transplantation (HSCT) Recipients

    by Parham Sadeghipour, Abbas Hajfathali, Farid Rashidi, Abolghsem Allahyari

  • Open Access

    Massive primary pulmonary artery rhabomyosarcoma: A case report

    by Farid Rashidi, Eissa Bilehjani, Seyed Ali Mousavi-Aghdas, Rezayat Parvizi

    Background: Pulmonary artery sarcomas (PAS) are rare tumours causing an insidiously progressive obstruction of the pulmonary circulation. The clinical presentation is often indistinguishable from chronic thromboembolic pulmonary hypertension (CTEPH). However, the atypical appearance of a heterogeneous filling defect in CT pulmonary angiography (CTPA) should prompt further investigation. Case Presentation: A previously healthy young man presented with massive haemoptysis, acute respiratory distress, and progressive exertional dyspnea since the year before. Echocardiography demonstrated severe right ventricular dysfunction and highly probable pulmonary hypertension. CTPA revealed an extensive filling defect with an appearance concerning PAS. Due to syncopal episodes at rest, the patient underwent urgent pulmonary artery endarterectomy (PEA). A massive tree-like tumour was excised as a result. Post-operatively, reperfusion injury and refractory pulmonary oedema mandated extracorporeal membrane oxygenation (ECMO). Unfortunately, ECMO was complicated with massive haemolysis and acute kidney injury. The patient succumbed to multi-organ failure. Through tissue analysis established a diagnosis of embryonal rhabdomyosarcoma. Discussion: Unfortunately, the patient had not reached out for his worsening dyspnea. PASs should not be mistaken for a thrombus and anticoagulation should be avoided. The urgent condition precluded biopsy and tissue diagnosis. Similarly, neoadjuvant chemotherapy was not feasible. Post-operatively, reperfusion injury and pulmonary oedema ensued, which mandated ECMO. This complication should be anticipated preoperatively. There is a need for more data on PASs to establish a consensus for management.


  • Open Access

    Clot Burden As a Predictor of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism: A Cohort Study

    by Esmaeil Gharepapagh, Fatemeh Rahimi, Ata Koohi, Hooman Bakhshandeh, Seyed Ali Mousavi-Aghdas, Parham Sadeghipoor, Ashraf Fakhari, Mehrad Amirnia, Reza Javadrashid, Farid Rashidi

    Pulmonary embolism,chronic thromboembolic pulmonary hypertension,computed tomography angiography,Qanadli index


  • Single-Center Experience of Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension: The Results from the Tabriz University Medical Sciences (TUMS) CTEPH Program

    by Rezayat Parvizi, Eisa Bilehjani, Babak Mahmoudian, Ata Koohi, Hooriah Shojaan, Khalil Ansarin, Farid Rashidi

    Introduction Pulmonary endarterectomy (PEA) remains the preferred and potentially curative option for patients with chronic thromboembolic pulmonary hypertension (CTEPH). This study aimed to report the results of PEA for CTEPH in a tertiary center in Tabriz, Iran. Methods We analyzed the results of 42 CTEPH patients undergoing PEA, who were enrolled in the Tabriz University of Medical Sciences (TUMS-CTEPH) from January 2016 to October 2020. The main outcome measures included the New York Heart Association (NYHA) functional classification, the 6-Minute Walk Distance, hemodynamic measures in right heart catheterization, morbidity, and mortality. Results There was a significant improvement in the NYHA function class (2.6 ± 0.5 vs 1.1 ± 0.34), mean pulmonary arterial pressure (47.1 ± 13 vs 27.9 ± 8 mm Hg), cardiac output (4.3 ± 1.06 vs 5.9 ± 1.2 L/min), and pulmonary vascular resistance (709.4 ± 297.5 vs 214 ± 77 dyn s/cm5). Fifteen patients (35%) developed complications. The most common complication (10 [23%]) was reperfusion injury. Also, postsurgical mortality was 4% during hospital admission and 1-year follow-up. Conclusion This is the first single-center report of PEA from Iran. Post-PEA and 1-year survival were acceptable as a referral center. PEA can be performed safe with low mortality. Greater awareness of PEA and patients' access to experienced CTEPH centers are important issues. The material is available as a preprint on Research Square. F. R. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: F. R., R. P., E. B., A. K., B. M., and K. A. The first draft of the manuscript was written by F. R. and R. P., and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Received: 28 August 2022 Accepted: 22 November 2022 Article published online: 19 January 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany